期刊文献+
共找到784篇文章
< 1 2 40 >
每页显示 20 50 100
Spinal cord biological safety of image-guided radiation therapy versus conventional radiation therapy 被引量:23
1
作者 Wanlong Xu Xilinbaoleri +2 位作者 Hao Liu Ruozheng Wang Jingping Bai 《Neural Regeneration Research》 SCIE CAS CSCD 2012年第35期2755-2760,共6页
Tumor models were simulated in purebred Beagles at the T9-10 levels of the spinal cord and treated with spinal image-guided radiation therapy or conventional radiation therapy with 50 or 70 Gy total radiation. Three m... Tumor models were simulated in purebred Beagles at the T9-10 levels of the spinal cord and treated with spinal image-guided radiation therapy or conventional radiation therapy with 50 or 70 Gy total radiation. Three months after radiation, neuronal injury at the T9-10 levels was observed, including reversible injury induced by spinal image-guided radiation therapy and apoptosis induced by conventional radiation therapy. The number of apoptotic cells and expression of the proapoptotic protein Fas were significantly reduced, but expression of the anti-apoptotic protein heat shock protein 70 was significantly increased after image-guided radiation therapy compared with the conventional method of the same radiation dose. Moreover, the spinal cord cell apoptotic index positively correlated with the ratio of Fas/heat shock protein 70. These findings indicate that 3 months of radiation therapy can induce a late response in the spinal cord to radiation therapy; image-guided radiation therapy is safer and results in less neuronal injury compared with conventional radiation therapy. 展开更多
关键词 Image-guided radiation therapy conventional radiation therapy spinal cord NEURONS apoptosis FAS heat shock protein 70 biological safety vertebral body TUMOR
下载PDF
Promising biological therapies for ulcerative colitis: A review of the literature 被引量:9
2
作者 Hirotada Akiho Azusa Yokoyama +7 位作者 Shuichi Abe Yuichi Nakazono Masatoshi Murakami Yoshihiro Otsuka Kyoko Fukawa Mitsuru Esaki Yusuke Niina Haruei Ogino 《World Journal of Gastrointestinal Pathophysiology》 CAS 2015年第4期219-227,共9页
Ulcerative colitis(UC) is a chronic lifelong condition characterized by alternating flare-ups and remission. There is no single known unifying cause, and the pathogenesis is multifactorial, with genetics, environmenta... Ulcerative colitis(UC) is a chronic lifelong condition characterized by alternating flare-ups and remission. There is no single known unifying cause, and the pathogenesis is multifactorial, with genetics, environmental factors, microbiota, and the immune system all playing roles. Current treatment modalities for UC include 5-aminosalicylates, corticosteroids, immunosuppressants(including purine antimetabolites, cyclosporine, and tacrolimus), and surgery. Therapeutic goals for UC are evolving. Medical treatment aims to induce remission and prevent relapse of disease activity. Infliximab, an anti-tumor necrosis factor(TNF)-α monoclonal antibody, is the first biological agent for the treatment of UC. Over the last decade, infliximab and adalimumab(anti-TNF-α agents) have been used for moderate to severe UC, and have been shown to be effective in inducing and maintaining remission. Recent studies have indicated that golimumab(another anti-TNF-α agent), tofacitinib(a Janus kinase inhibitor), and vedolizumab and etrolizumab(integrin antagonists), achieved good clinical remission and response rates in UC. Recently, golimumab and vedolizumab have been approved for UC by the United States Food and Drug Administration. Vedolizumab may be used as a first-line alternative to anti-TNF-α therapy in patients with an inadequate response to corticosteroids and/or immunosuppressants. Here, we provide updated information on various biological agents in the treatment of UC. 展开更多
关键词 ULCERATIVE COLITIS biological therapy ANTITUMOR NE
下载PDF
Biological therapy for dermatological manifestations of inflammatory bowel disease 被引量:5
3
作者 Maddalena Zippi Roberta Pica +1 位作者 Daniela De Nitto Paolo Paoluzi 《World Journal of Clinical Cases》 SCIE 2013年第2期74-78,共5页
Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease(IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not... Ulcerative colitis and Crohn's disease are the two forms of inflammatory bowel disease(IBD). The advent of biological drugs has significantly changed the management of these conditions. Skin manifestations are not uncommon in IBD. Among the reactive lesions(immunemediated extraintestinal manifestations), erythema nodosum(EN) and pyoderma gangrenosum(PG) are the two major cutaneous ills associated with IBD, while psoriasis is the dermatological comorbidity disease observed more often. In particular, in the last few years, anti-tumor necrosis factor(TNF)-α agents have been successfully used to treat psoriasis, especially these kinds of lesions that may occur during the treatment with biological therapies. The entity of the paradoxical manifestations has been relatively under reported as most lesions are limited and a causal relationship with the treatment is often poorly understood. The reason for this apparent side-effect of the therapy still remains unclear. Although side effects may occur, their clinical benefits are undoubted. This article reviews the therapeutic effects of the two most widely used anti-TNF-α molecules, infliximab(a fusion protein dimer of the human TNF-α receptor) and adalimumab(a fully human monoclonal antibody to TNF-α), for the treatment of the major cutaneous manifestations associated with IBD(EN, PG and psoriasis). 展开更多
关键词 biological THERAPIES ERYTHEMA nodosum Inflammatory BOWEL disease PSORIASIS PYODERMA gangrenosum
下载PDF
Biological therapy for ulcerative colitis:An update 被引量:5
4
作者 Geom Seog Seo Soo-Cheon Chae 《World Journal of Gastroenterology》 SCIE CAS 2014年第37期13234-13238,共5页
Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-&#x003b1; agents infliximab and adalimumab have been used in large-scale clinical trials and are currently... Of the diverse biological agents used for patients with ulcerative colitis, the anti-tumor necrosis factor-&#x003b1; agents infliximab and adalimumab have been used in large-scale clinical trials and are currently widely used in the treatment of inflammatory bowel disease patients. Recent studies have indicated that golimumab, oral tofacitinib and vedolizumab reportedly achieved good clinical response and remission rates in ulcerative colitis patients. Thus, we believe that the detailed investigation of various studies on clinical trials may provide important information for the selection of appropriate biological agents, and therefore, we have extensively reviewed such trials in the present study. 展开更多
关键词 Ulcerative colitis Immune dysfunction biological therapy REMISSION Clinical trial Inflammatory bowel disease
下载PDF
Rare extraintestinal manifestations of ulcerative colitis treated with dual biologic therapy:A case report
5
作者 Aleksandra Filipiuk Maciej Gonciarz 《World Journal of Clinical Cases》 SCIE 2024年第23期5441-5447,共7页
BACKGROUND Ulcerative colitis(UC)is an idiopathic,chronic inflammatory bowel disease(IBD)most often located in the rectum,but may involve the entire colon.Extra intestinal manifestations(EIMs)occur with varying freque... BACKGROUND Ulcerative colitis(UC)is an idiopathic,chronic inflammatory bowel disease(IBD)most often located in the rectum,but may involve the entire colon.Extra intestinal manifestations(EIMs)occur with varying frequency depending on the affected organ.The most common ones are musculoskeletal EIMs,affecting up to 33%-40%of IBD patients.These include,among others,inflammatory back pain,tendinitis,plantar fasciitis and arthritis.Only a few case reports in literature discuss Achilles tendinitis.CASE SUMMARY This report describes a patient with UC and Achilles tendinitis in whom after many unsuccessful attempts of treatment with sulfasalazine,mesalazine,glucocorticosteroids,infliximab and tofacitinib,a complete UC remission and resolution of Achilles tendinitis were achieved with the use of dual biologic therapy(DBT)-ustekinumab and adalimumab(ADA).CONCLUSION This case mentions rare EIMs of UC and suggests that DBT may be an alternative for patient with ulcerative colitis and EIMs. 展开更多
关键词 Achilles tendinitis Dual biologic therapy Extraintestinal manifestations SPONDYLOARTHROPATHY Ulcerative colitis Case report
下载PDF
Biological scaffold as potential platforms for stem cells:Current development and applications in wound healing
6
作者 Jie-Yu Xiang Lin Kang +7 位作者 Zi-Ming Li Song-Lu Tseng Li-Quan Wang Tian-Hao Li Zhu-Jun Li Jiu-Zuo Huang Nan-Ze Yu Xiao Long 《World Journal of Stem Cells》 SCIE 2024年第4期334-352,共19页
Wound repair is a complex challenge for both clinical practitioners and researchers.Conventional approaches for wound repair have several limitations.Stem cell-based therapy has emerged as a novel strategy to address ... Wound repair is a complex challenge for both clinical practitioners and researchers.Conventional approaches for wound repair have several limitations.Stem cell-based therapy has emerged as a novel strategy to address this issue,exhibiting significant potential for enhancing wound healing rates,improving wound quality,and promoting skin regeneration.However,the use of stem cells in skin regeneration presents several challenges.Recently,stem cells and biomaterials have been identified as crucial components of the wound-healing process.Combination therapy involving the development of biocompatible scaffolds,accompanying cells,multiple biological factors,and structures resembling the natural extracellular matrix(ECM)has gained considerable attention.Biological scaffolds encompass a range of biomaterials that serve as platforms for seeding stem cells,providing them with an environment conducive to growth,similar to that of the ECM.These scaffolds facilitate the delivery and application of stem cells for tissue regeneration and wound healing.This article provides a comprehensive review of the current developments and applications of biological scaffolds for stem cells in wound healing,emphasizing their capacity to facilitate stem cell adhesion,proliferation,differentiation,and paracrine functions.Additionally,we identify the pivotal characteristics of the scaffolds that contribute to enhanced cellular activity. 展开更多
关键词 Stem-cell-based therapy biological scaffolds Wound healing Extracellular matrix mimicry Cellular activities enhancement Scaffold characteristics
下载PDF
Deterministic Parsing Model of the Compound Biological Effectiveness (<i>CBE</i>) Factor for Intracellular <sup>10</sup>Boron Distribution in Boron Neutron Capture Therapy 被引量:2
7
作者 Shintaro Ishiyama 《Journal of Cancer Therapy》 2014年第14期1388-1398,共11页
Purpose: In defining the biological effects of the 10B(n, α)7Li neutron capture reaction, we have previously developed a deterministic parsing model to determine the Compound Biological Effectiveness (CBE) factor in ... Purpose: In defining the biological effects of the 10B(n, α)7Li neutron capture reaction, we have previously developed a deterministic parsing model to determine the Compound Biological Effectiveness (CBE) factor in Borono-Phenyl-Alanine (BPA)-mediated Boron Neutron Capture Therapy (BNCT). In present paper, we demonstrate that the CBE factor is directly and unambiguously derivable by the new formula for any case of intracellular 10Boron (10B) distribution, which is founded on this model for tissues and tumor. Method: To determine the CBE factor, we derive the following new calculation formula founded on the deterministic parsing model with three constants, CBE0, F, n and the eigen value Nth/Nmax. where, Nth and Nmax are the threshold value of boron concentration of N and saturation boron density in tissues and tumor. In order to determine these constants and the eigen values, iterative calculation technique was employed for the CEB factor and Nmax data set previously reported. Results and Conclusion: From the iterative calculation results, it is clear that the calculated CBE factor values obtained are almost identical to the original CBE factors and there is a good correlation between the original CBE factors and Nth/Nmax, when CBE0, F and n are given as 0.5, 8 and 3, respectively. These constants provide a better understanding of different types of intracellular10B distribution. 展开更多
关键词 Boron Neutron Capture therapy COMPOUND biological Effectiveness Borono-Phenyl-Alanine Tumor 10B(n α)7Li
下载PDF
Improving cancer therapy by combining cell biological, physical, and molecular targeting strategies 被引量:1
8
作者 Jac A. Nickoloff 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第1期7-9,共3页
Successful cancer therapy depends on selective killing of tumor cells while sparing normal cells. Selectivity can be achieved through treatment strategies that target tumor cells. A recent report from the Li laborato... Successful cancer therapy depends on selective killing of tumor cells while sparing normal cells. Selectivity can be achieved through treatment strategies that target tumor cells. A recent report from the Li laboratory (1) describes an elegant strategy to selectively kill tumor cells by combining several targeting strategies based on cell biological, physical, and molecular (genetic) properties of tumor and normal cells that enhances tumor cell killing in vitro and in an in vivo tumor xenograft model. The idea of using a multiplex targeting approach is reminiscent of strategies in which several antibiotics are used to treat bacterial infections while minimizing the chance that rare antibiotic-resistant mutants will arise within a population. 展开更多
关键词 CELL and molecular targeting strategies PHYSICAL Improving cancer therapy by combining cell biological DNA DSB
下载PDF
Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy 被引量:2
9
作者 Klaudia Farkas Péter László Lakatos +8 位作者 Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár 《World Journal of Gastroenterology》 SCIE CAS 2014年第11期2995-3001,共7页
AIM: To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn&... AIM: To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn&#x02019;s disease (CD) and ulcerative colitis (UC). 展开更多
关键词 Crohn’ s disease Ulcerative colitis biological therapy Endoscopy Mucosal healing
下载PDF
Biological Dose Estimation Model for Proton Beam Therapy
10
作者 Vladimir Anferov Indra J. Das 《International Journal of Medical Physics, Clinical Engineering and Radiation Oncology》 2015年第2期149-161,共13页
Purpose: The recommended value for the relative biological effectiveness (RBE) of proton beams is currently assumed to be 1.1. However, there is increasing evidence that RBE increases towards the end of proton beam ra... Purpose: The recommended value for the relative biological effectiveness (RBE) of proton beams is currently assumed to be 1.1. However, there is increasing evidence that RBE increases towards the end of proton beam range that may increase the biological effect of proton beam in the distal regions of the dose deposition. Methods: A computational approach is presented for estimating the biological effect of the proton beam. It includes a method for calculating the dose averaged linear energy transfer (LET) along the measured Bragg peak and published LET to RBE conversion routine. To validate the proposed method, we have performed Monte Carlo simulations of the pristine Bragg peak at various beam energies and compared the analysis with the simulated results. A good agreement within 5% is observed between the LET analysis of the modeled Bragg peaks and Monte Carlo simulations. Results: Applying the method to the set of Bragg peaks measured at a proton therapy facility we have estimated LET and RBE values along each Bragg peak. Combining the individual RBE-weighted Bragg peaks with known energy modulation weights we have calculated the RBE-weighted dose in the modulated proton beam. The proposed computational method provides a tool for calculating dose averaged LET along the measured Bragg peak. Conclusions: Combined with a model to convert LET into RBE, this method enables calculation of RBE-weighted dose both in pristine Bragg peak and in modulated beam in proton therapy. 展开更多
关键词 PROTON Beam therapy RELATIVE biological EFFECTIVENESS Linear Energy TRANSFER
下载PDF
Biological Therapy in IBD—Is There Any Optimal End Point?
11
作者 Klaudia Farkas Tamás Molnár 《Health》 2014年第11期1296-1299,共4页
Biological therapy has been used in the treatment of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) for more than a decade. Although guidelines exist on how to start and adjust biologi... Biological therapy has been used in the treatment of inflammatory bowel disease (IBD-Crohn’s disease [CD], ulcerative colitis [UC]) for more than a decade. Although guidelines exist on how to start and adjust biological therapy, information on when and how it should be stopped is still scarce. In this review, our aim is to summarize the results of the recently published papers on the outcome of the discontinuation of biological therapy in patients with CD and UC. 展开更多
关键词 Crohn’s Disease ULCERATIVE COLITIS biological therapy DISCONTINUATION
下载PDF
Effects of Vital Message Therapy on Biological Response Modulation-An Experimental Study
12
作者 Meng Xianjun Xu Yingxin(Institue of Basic Medical Science General Hospital of Chinese PLA)Zheng Xuewen(China Vital Message institute) 《中国针灸》 CAS CSCD 北大核心 1995年第S2期238-239,共2页
EffectsofVitalMessageTherapyonBiologicalResponseModulation-AnExperimentalStudy¥MengXianjun;XuYingxin(Institu... EffectsofVitalMessageTherapyonBiologicalResponseModulation-AnExperimentalStudy¥MengXianjun;XuYingxin(InstitueofBasicMedicalSc... 展开更多
关键词 therapy Modula VITAL biolog
下载PDF
Renal Replacement Therapy in a Caribbean Population: The Impact of Biological, Sociocultural and Demographic Factors
13
作者 Sharlene Sanchez Aruna Rampersad +3 位作者 Cathy-Lee Jagdeo Patrice Ayuen Chanelle Gunness George Legall 《International Journal of Clinical Medicine》 2018年第3期142-161,共20页
Background: The options for renal replacement therapy for end stage renal disease include haemodialysis (HD), peritoneal dialysis (PD) and renal transplantation. In this study demographic, sociocultural and biological... Background: The options for renal replacement therapy for end stage renal disease include haemodialysis (HD), peritoneal dialysis (PD) and renal transplantation. In this study demographic, sociocultural and biological factors were assessed over a 1-year period for patients on renal replacement therapy. Methods: This cross-sectional study included all patients 18 years and older and on renal replacement therapy for at least 3 months in Trinidad and Tobago. Five hundred and thirty participants were recruited from our organ transplantation unit, all centres facilitating PD and a stratified random sample of all HD centres (100 T, 80 PD, 350 HD from October 2015 to October 2016. A questionnaire was administered and included demographics, knowledge and understanding and biological factors impacting on renal replacement therapy. Results: Thirty eight percent of all patients were between 56 to 65 years of age. The Indo Trinidadian population accounted for 51% of the subjects. 52.5% were male and 47.5% were female. From the data, 72% of patients were diabetic and/or hypertensive. In the transplant recipients, 39% were diabetic and/or hypertensive and 27% reported chronic glomerulonephritis as the aetiology of their kidney failure. The diagnosis of chronic kidney disease was made when patients were at end stage renal disease requiring intervention in 84.2% of persons. The employed population of patients constituted 65% of renal transplant recipients, 43.75% of peritoneal dialysis patients and 22.86% of haemodialysis patients. The patient’s physician had the greatest influence on renal replacement therapy choice (85.4% haemodialysis, 85% peritoneal dialysis, 71% transplant). Conclusions: In this cohort of 530 patients on renal replacement therapy, knowledge of therapy and physician’s influence were some of the factors that impacted on choice of therapy. Most patients were already de novo end stage renal disease when the diagnosis of kidney disease was made. Lifestyle diseases-type 2 diabetes mellitus and hypertension were the main causative diseases contributing to renal failure. This study which is the first in the Caribbean to evaluate biological, sociocultural and demographic factors in patients receiving renal replacement will better assist in prevention strategies and resource allocation. 展开更多
关键词 RENAL REPLACEMENT therapy SOCIOCULTURAL biological
下载PDF
Role of conventional therapies in the era of biological treatment in Crohn’s disease
14
作者 Paolo Gionchetti Carlo Calabrese +7 位作者 Rosy Tambasco Ramona Brugnera Giulia Straforini Giuseppina Liguori Giulia Spuri Fornarini Donatella Riso Massimo Campieri Fernando Rizzello 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第14期1797-1806,共10页
Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentra... Outstanding progress regarding the pathophysiology of Crohn's disease (CD) has led to the development of innovative therapeutic concepts. Numerous controlled trials have been performed in CD. This review concentrates on the results of randomized,placebo-controlled trials,and meta-analyses when available,that provide the highest degree of evidence. Current guidelines on the management of CD recommend a step-up approach to treatment involving the addition of more powerful therapies as the severity of disease and refractoriness to therapy increase. The advent of biological drugs has opened new therapeutic horizons for treating CD,modifying the treatment goals. However,the large majority of patients with CD will be managed through conventional therapy,even if they are a prelude to biological therapy. 展开更多
关键词 Crohn’s disease SULFASALAZINE 5-Aminosalicylic acid AZATHIOPRINE 6-MERCAPTOPURINE biological therapies Anti-tumor necrosis facto-α
下载PDF
The biological clock: future of neurological disorders therapy
15
作者 Sagar Gaikwad 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第3期567-568,共2页
Dear editors, The seminal, discoveries by Jeffrey Connor Hall, Michael Rosbash and Michael Warren Young have earned the Nobel Prize in Physiology and Medicine 2017 for revealing a crucial physiological mechanism expla... Dear editors, The seminal, discoveries by Jeffrey Connor Hall, Michael Rosbash and Michael Warren Young have earned the Nobel Prize in Physiology and Medicine 2017 for revealing a crucial physiological mechanism explaining biological clock, with important implications for human health and diseases. The work explains the interplay between the biological clock, the transcriptional feedback loop, and neuroscience, where they identified genes and proteins that work together both in humans and other animals. This article describes the link between biological clock disruption and consequent neurodegeneration and also highlights the significance of biological clock modulators for possible clinical interventions in neurological disorders. 展开更多
关键词 The biological clock future of neurological disorders therapy
下载PDF
Advances in biological immunotherapy for gastric cancer:a mini-review
16
作者 Wan-Qiu Lu 《TMR Cancer》 2020年第2期74-83,共10页
Gastric cancer immunotherapy refers to the use of biological technology to mobilize the immune function so that the body has a natural anti-cancer ability.It can be induced in vitro by collecting immune cells and canc... Gastric cancer immunotherapy refers to the use of biological technology to mobilize the immune function so that the body has a natural anti-cancer ability.It can be induced in vitro by collecting immune cells and cancer cells from patients with gastric cancer to form specific immune cell groups.Besides,a large number of these immune cell groups are cultured,separated,and then reinfused into patients,to achieve high efficiency,eliminate tumors and mobilize immune mechanisms in patients.In theory,this method can cure tumors because the principle of immunotherapy is to stimulate the body's autoimmune response.However,for some special populations,there may be more severe side effects.At present,the prediction,prevention,and treatment of this severe side effect are not complete.The immunotherapy of gastric cancer has not yet reached the full promotion,but it is a good treatment direction.It can be used clinically with chemotherapy and radiotherapy,surgery and traditional Chinese medicine cooperate,thereby achieving significant curative effects,and even curing gastric cancer. 展开更多
关键词 Gastric cancer biological immunotherapy Cell immunotherapy Tumor vaccine therapy Adoptive immunotherapy
下载PDF
Recent biological trends in management of fracture non-union 被引量:13
17
作者 Khaled M Emara Ramy Ahmed Diab Ahmed Khaled Emara 《World Journal of Orthopedics》 2015年第8期623-628,共6页
Bone regeneration is a complex, well-orchestrated physiological process of bone formation, which can be seen during normal fracture healing, and is involved in continuous remodelling throughout adult life. Currently,t... Bone regeneration is a complex, well-orchestrated physiological process of bone formation, which can be seen during normal fracture healing, and is involved in continuous remodelling throughout adult life. Currently,there is a plethora of different strategies to augment the impaired or "insufficient" bone-regeneration process, including the "gold standard" autologous bone graft, free fibula vascularised graft, allograft implantation, and use of growth factors, osteoconductive scaffolds, osteoprogenitor cells and distraction osteogenesis. Improved "local" strategies in terms of tissue engineering and gene therapy, or even "systemic" enhancement of bone repair, are under intense investigation, in an effort to overcome the limitations of the current methods, to produce bone-graft substitutes with biomechanical properties that are as identical to normal bone as possible, to accelerate the overall regeneration process, or even to address systemic conditions, such as skeletal disorders and osteoporosis. An improved understanding of the molecular and cellular events that occur during bone repair and remodeling has led to the development of biologic agents that can augment the biological microenvironment and enhance bone repair. Orthobiologics, including stem cells, osteoinductive growth factors, osteoconductive matrices, and anabolic agents, are available clinically for accelerating fracture repair and treatment of compromised bone repair situations like delayed unions and nonunions. A lack of standardized outcome measures for comparison of biologic agents in clinical fracture repair trials, frequent off-label use, and a limited understanding of the biological activity of these agents at the bone repair site have limited their efficacy in clinical applications. 展开更多
关键词 biological FRACTURE repair NONUNION Cell therapy BONE SUBSTITUTES
下载PDF
Biological effects of radiation on cancer cells 被引量:7
18
作者 Jin-Song Wang Hai-Juan Wang Hai-Li Qian 《Military Medical Research》 CAS 2018年第4期350-360,共11页
With the development of radiotherapeutic oncology, computer technology and medical imaging technology, radiation therapy has made great progress. Research on the impact and the specific mechanism of radiation on tumor... With the development of radiotherapeutic oncology, computer technology and medical imaging technology, radiation therapy has made great progress. Research on the impact and the specific mechanism of radiation on tumors has become a central topic in cancer therapy. According to the traditional view, radiation can directly affect the structure of the DNA double helix, which in turn activates DNA damage sensors to induce apoptosis, necrosis, and aging or affects normal mitosis events and ultimately rewires various biological characteristics of neoplasm cells. In addition, irradiation damages subcellular structures, such as the cytoplasmic membrane, endoplasmic reticulum, ribosome, mitochondria, and lysosome of cancer cells to regulate various biological activities of tumor cells. Recent studies have shown that radiation can also change the tumor cell phenotype, immunogenicity and microenvironment, thereby globally altering the biological behavior of cancer cells. In this review, we focus on the effects of therapeutic radiation on the biological features of tumor cells to provide a theoretical basis for combinational therapy and inaugurate a new era in oncology. 展开更多
关键词 RADIATION CANCER CELLS biological features Combinational therapy
下载PDF
Biomedical overview of melanin.1.Updating melanin biology and chemistry,physico-chemical properties,melanoma tumors,and photothermal therapy 被引量:2
19
作者 ALFONSO BLÁZQUEZ-CASTRO JUAN CARLOS STOCKERT 《BIOCELL》 SCIE 2021年第4期849-862,共14页
Melanins(eumelanin,pheomelanin,and allomelanin)represent a very,if not themost,important group of biological pigments.Their biological roles are multiple,from photoprotection to antioxidant activity,heavy metal dispos... Melanins(eumelanin,pheomelanin,and allomelanin)represent a very,if not themost,important group of biological pigments.Their biological roles are multiple,from photoprotection to antioxidant activity,heavy metal disposal or the myriad uses of color in organisms across all Phyla.In the first part of this review,eumelanin biology and some chemical aspects will be presented,as well as key physico-chemical features that make this biological pigment so interesting.The principal characteristics of the melanocyte,the melanin-synthesizing cell in mammals,will also be introduced.Transformed melanocytes are the cause of one of the most devastating known cancers:the malignant melanoma.Epidemiology and molecular signaling aspects will be presented next,as well as the principal advances in promising oncotherapies designed and applied for the treatment of melanoma.In particular,on account of the photo-physical properties of melanin,special details will be provided regarding the use of photothermal therapy for melanoma treatment. 展开更多
关键词 Antitumor therapies biological pigments MELANIN MELANOMA Photothermal therapy Skin tumors
下载PDF
Determination of the Compound Biological Effectiveness (CBE) Factors Based on the <i>ISHIYAMA-IMAHORI</i>Deterministic Parsing Model with the Dynamic PET Technique 被引量:2
20
作者 Shintaro Ishiyama Yoshio Imahori +1 位作者 Jun Itami Hanna Koivunoro 《Journal of Cancer Therapy》 2015年第8期759-766,共8页
Purpose: In defining the biological effects of the 10B(n, α)7Li neutron capture reaction, we have proposed a deterministic parsing model (ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness (CB... Purpose: In defining the biological effects of the 10B(n, α)7Li neutron capture reaction, we have proposed a deterministic parsing model (ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness (CBE) factor in Borono-Phenyl-Alanine (BPA)-mediated Boron Neutron Capture Therapy (BNCT). In present paper, we demonstrate a specific method of how the application of the case of application to actual patient data, which is founded on this model for tissues and tumor. Method: To determine the CBE factor, we derived the following new calculation formula founded on the deterministic parsing model with three constants, CBE0, F, n and the eigen value Nth/Nmax.? (1), where, Nth and Nmax are the threshold value of boron concentration of N and saturation boron density and CBE0, F and n are given as 0.5, 8 and 3, respectively. In order to determine Nth and Nmax in the formula, sigmoid logistic function was employed for 10B concentration data, Db(t) obtained by dynamic PET technique. (2), where, A, a and t0 are constants. Results and Conclusion: From the application of sigmoid function to dynamic PET data, it is concluded that the Nth and Nmax for tissue and tumor are identified with the parameter constants in the sigmoid function in Equation (2) as: (3). And the calculated CBE factor values obtained from Equation (1), with Nth/Nmax. 展开更多
关键词 Boron Neutron Capture therapy COMPOUND biological Effectiveness Borono-Phenyl-Alanine Tumor 10B(n α)7Li SIGMOID Function
下载PDF
上一页 1 2 40 下一页 到第
使用帮助 返回顶部